BACKGROUND: With decreased rates of HIV mortality and disease progression attributable to treatment with nucleoside analogue reverse transcriptase inhibitors (NRTIs), attention has now become focused on the toxicities of these forms of treatment. It is believed NRTIs cause a decrease in mitochondrial DNA (mtDNA) synthesis due to their inhibition of DNA polymerase gamma. This hypothesis is supported by in vitro data from muscle biopsies and human lymphoblastic cell lines. The resulting mitochondrial toxicity is thought to manifest itself in a variety of clinical symptoms including fatigue, fat wasting and peripheral neuropathy. A non-invasive test of mitochondrial toxicity is needed to assess toxicity and optimise HIV treatment strategies. Peripheral blood mononuclear cells (PBMC) and subcutaneous fat could be ideal and accessible sources of mtDNA for examining toxicity. OBJECTIVES: The objectives of this study were (a) to develop an assay to quantify the mtDNA copy number of PBMC and obtain reproducible results and (b) to establish the utility of subcutaneous fat as a source of mtDNA for quantification. STUDY DESIGN: PBMC were isolated from blood by centrifugation over Ficoll-Paque and subcutaneous fat was obtained from two 3 mm punch skin biopsies. Following DNA extraction, the mtDNA copy number in each sample was quantified by real-time polymerase chain reaction (PCR). RESULTS: The real-time PCR assay was found to generate consistent and reproducible results with replicates of samples undertaken within the same run, and in two or more different runs, having a mean coefficient of variation of 11.3 and 17.2%, respectively. PBMC and subcutaneous fat contained 409+/-148 and 2042+/-391 copies of mtDNA per cell, respectively. CONCLUSIONS: From the work carried out it can be concluded that firstly, the real-time PCR assay generates consistent and reproducible results, and secondly that mtDNA can be extracted and quantified from PBMC and subcutaneous fat.
BACKGROUND: With decreased rates of HIV mortality and disease progression attributable to treatment with nucleoside analogue reverse transcriptase inhibitors (NRTIs), attention has now become focused on the toxicities of these forms of treatment. It is believed NRTIs cause a decrease in mitochondrial DNA (mtDNA) synthesis due to their inhibition of DNA polymerase gamma. This hypothesis is supported by in vitro data from muscle biopsies and human lymphoblastic cell lines. The resulting mitochondrial toxicity is thought to manifest itself in a variety of clinical symptoms including fatigue, fat wasting and peripheral neuropathy. A non-invasive test of mitochondrial toxicity is needed to assess toxicity and optimise HIV treatment strategies. Peripheral blood mononuclear cells (PBMC) and subcutaneous fat could be ideal and accessible sources of mtDNA for examining toxicity. OBJECTIVES: The objectives of this study were (a) to develop an assay to quantify the mtDNA copy number of PBMC and obtain reproducible results and (b) to establish the utility of subcutaneous fat as a source of mtDNA for quantification. STUDY DESIGN: PBMC were isolated from blood by centrifugation over Ficoll-Paque and subcutaneous fat was obtained from two 3 mm punch skin biopsies. Following DNA extraction, the mtDNA copy number in each sample was quantified by real-time polymerase chain reaction (PCR). RESULTS: The real-time PCR assay was found to generate consistent and reproducible results with replicates of samples undertaken within the same run, and in two or more different runs, having a mean coefficient of variation of 11.3 and 17.2%, respectively. PBMC and subcutaneous fat contained 409+/-148 and 2042+/-391 copies of mtDNA per cell, respectively. CONCLUSIONS: From the work carried out it can be concluded that firstly, the real-time PCR assay generates consistent and reproducible results, and secondly that mtDNA can be extracted and quantified from PBMC and subcutaneous fat.
Authors: Jason Y Y Wong; Wei Hu; George S Downward; Wei Jie Seow; Bryan A Bassig; Bu-Tian Ji; Fusheng Wei; Guoping Wu; Jihua Li; Jun He; Chin-San Liu; Wen-Ling Cheng; Yunchao Huang; Kaiyun Yang; Ying Chen; Nathaniel Rothman; Roel C Vermeulen; Qing Lan Journal: Carcinogenesis Date: 2017-09-01 Impact factor: 4.944
Authors: Stephen B Williams; Yuanqing Ye; Maosheng Huang; David W Chang; Ashish M Kamat; Xia Pu; Colin P Dinney; Xifeng Wu Journal: Cancer Prev Res (Phila) Date: 2015-04-20
Authors: Rhiannon E Lloyd; Joon-Hee Lee; Ramiro Alberio; Emma J Bowles; João Ramalho-Santos; Keith H S Campbell; Justin C St John Journal: Genetics Date: 2006-02-01 Impact factor: 4.562
Authors: Jinliang Xing; Meng Chen; Christopher G Wood; Jie Lin; Margaret R Spitz; Jianzhong Ma; Christopher I Amos; Peter G Shields; Neal L Benowitz; Jian Gu; Mariza de Andrade; Gary E Swan; Xifeng Wu Journal: J Natl Cancer Inst Date: 2008-07-29 Impact factor: 13.506
Authors: Francis J Miller; Franklin L Rosenfeldt; Chunfang Zhang; Anthony W Linnane; Phillip Nagley Journal: Nucleic Acids Res Date: 2003-06-01 Impact factor: 16.971